Is Salarius Pharmaceuticals Inc (SLRX) Stock About to Get Hot Tuesday?

Overall market sentiment has been down on Salarius Pharmaceuticals Inc (SLRX) stock lately. SLRX receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Salarius Pharmaceuticals Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on SLRX!

See Full SLRX Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With SLRX Stock Today?

Salarius Pharmaceuticals Inc (SLRX) stock is trading at $2.58 as of 3:43 PM on Tuesday, Jan 31, an increase of $0.13, or 5.31% from the previous closing price of $2.45. The stock has traded between $2.43 and $2.75 so far today. Volume today is less active than usual. So far 104,998 shares have traded compared to average volume of 340,312 shares. To screen for more stocks like Salarius Pharmaceuticals Inc click here.

More About Salarius Pharmaceuticals Inc

Salarius Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing potential new cancer medicines for patients in need of new treatment options. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader. Click Here to get the full Stock Report for Salarius Pharmaceuticals Inc stock.